Gordon McKee MP: written questions
4 Jul 2026–16 Oct 2026 · year in progress
How these years work
Our reporting years run from 4 July to 3 July, starting with the 2024 general election. They are not official parliamentary sessions. Office costs keep IPSA’s April–March financial years. Records may cover only part of a year; a missing record does not mean no work was done.
Read what this MP said, asked and contributed in Parliament.
11 published records · newest first.
Written questions
Cancer: Health ServicesDepartment of Health and Social CareTabled 16 Jul 2026AnsweredUIN 19627More
Question: To ask the Secretary of State for Health and Social Care, what measurable improvements in (a) workforce capacity, (b) research activity, (c) clinical trial access, (d) speed of diagnosis and (e) patient outcomes are expected as a result of the work of the
Answer: The National Cancer Plan, published on 4 February 2026, sets out the Government's long-term approach to improving outcomes for all cancer patients, including those affected by rare cancers such as brain tumours. As part of the plan, the Government committ...
Answered 7 Sept 2026
Original Parliament recordNational Cancer BoardDepartment of Health and Social CareTabled 16 Jul 2026AnsweredUIN 19626More
Question: To ask the Secretary of State for Health and Social Care, what key performance indicators and outcome measures will be used to assess the effectiveness of the National Cancer Board; who will be responsible for overseeing delivery of those outcomes; where
Answer: The National Cancer Plan, published on 4 February 2026, sets out the Government's long-term approach to improving outcomes for all cancer patients, including those affected by rare cancers such as brain tumours. As part of the plan, the Government committ...
Answered 7 Sept 2026
Original Parliament recordBrain Cancer: Health ServicesDepartment of Health and Social CareTabled 16 Jul 2026AnsweredUIN 19625More
Question: To ask the Secretary of State for Health and Social Care, whether his department will consider the appointment of a specific National Clinical Lead for Brain Cancers.
Answer: The National Cancer Plan, published on 4 February 2026, sets out the Government's long-term approach to improving outcomes for all cancer patients, including those affected by rare cancers such as brain tumours. As part of the plan, the Government committ...
Answered 7 Sept 2026
Original Parliament recordCancer: Health ServicesDepartment of Health and Social CareTabled 16 Jul 2026AnsweredUIN 19624More
Question: To ask the Secretary of State for Health and Social Care, whether the (a) National Clinical Lead for Rare Cancers and (b) Rare Cancer Specialty Lead have been appointed; if so, on what date, and against which National Cancer Plan commitments they will be
Answer: The National Cancer Plan, published on 4 February 2026, sets out the Government's long-term approach to improving outcomes for all cancer patients, including those affected by rare cancers such as brain tumours. As part of the plan, the Government committ...
Answered 7 Sept 2026
Original Parliament recordCancer: Health ServicesDepartment of Health and Social CareTabled 16 Jul 2026AnsweredUIN 19623More
Question: To ask the Secretary of State for Health and Social Care, which recommendations relating to the cancer workforce from previous workforce reviews, task and finish groups, and National Cancer Board workstreams remain outstanding; what assessment has been ma
Answer: The National Cancer Plan, published on 4 February 2026, sets out the Government's long-term approach to improving outcomes for all cancer patients, including those affected by rare cancers such as brain tumours. As part of the plan, the Government committ...
Answered 7 Sept 2026
Original Parliament recordBrain Cancer: Health ServicesDepartment of Health and Social CareTabled 16 Jul 2026AnsweredUIN 19622More
Question: To ask the Secretary of State for Health and Social Care, by what date liquid biopsy technologies will be routinely available for brain tumour patients across the NHS; how many additional patients are expected to gain access to targeted or repurposed trea
Answer: While no specific assessment has been made of when liquid biopsy technologies will be routinely available for brain tumour patients or the resulting access to targeted treatments, the National Cancer Plan for England commits to expand biomarker testing ov...
Answered 7 Sept 2026
Original Parliament recordBrain Cancer: Health ServicesDepartment of Health and Social CareTabled 16 Jul 2026AnsweredUIN 19621More
Question: To ask the Secretary of State for Health and Social Care, what formal mechanisms are in place to ensure that the views of patients, families and brain cancer patient advocacy organisations are reflected in the work of the National Clinical Lead for Rare C
Answer: The National Cancer Plan, published on 4 February 2026, sets out the Government's long-term approach to improving outcomes for all cancer patients, including those affected by rare cancers such as brain tumours. As part of the plan, the Government committ...
Answered 7 Sept 2026
Original Parliament recordNHS: VacanciesDepartment of Health and Social CareTabled 15 Jul 2026AnsweredUIN 19217More
Question: To ask the Secretary of State for Health and Social Care, what discussions he has had with the devolved administrations on developing a coordinated UK approach to addressing shortages in the NHS workforce in key specialties.
Answer: While planning of the health workforce is devolved in the United Kingdom, specialty training recruitment is undertaken on a UK-wide basis. The UK National Recruitment Board oversees specialty training on behalf of the four UK health departments.The new re...
Answered 1 Sept 2026
Original Parliament recordRare Diseases: GeneticsDepartment of Health and Social CareTabled 14 Jul 2026AnsweredUIN 18849More
Question: To ask the Secretary of State for Health and Social Care, what steps the Department is taking to improve interoperability between rare-disease registries and genomic-data systems across the UK.
Answer: The Government is committed to ensuring that all patients across the UK have access to cutting-edge clinical trials and innovative, lifesaving treatments, and we are working with the devolved administrations, delivery partners across the health system, an...
Answered 25 Aug 2026
Original Parliament recordClinical TrialsDepartment of Health and Social CareTabled 14 Jul 2026AnsweredUIN 18848More
Question: To ask the Secretary of State for Health and Social Care, what steps the Department is taking with the devolved administrations to increase the number of patients able to participate in commercial clinical trials across the UK.
Answer: The Government is committed to ensuring that all patients across the UK have access to cutting-edge clinical trials and innovative, lifesaving treatments, and we are working with the devolved administrations, delivery partners across the health system, an...
Answered 25 Aug 2026
Original Parliament recordMedical Equipment: CybersecurityDepartment of Health and Social CareTabled 13 Jul 2026AnsweredUIN 18295More
Question: To ask the Secretary of State for Health and Social Care, how many cybersecurity vulnerabilities affecting medical devices have been reported to the Medicines and Healthcare products Regulatory Agency in each of the last three years.
Answer: The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring medicines, medical devices, and blood components for transfusion meet applicable standards of safety, quality, and efficacy. The MHRA rigorously assesses available ...
Answered 20 Jul 2026
Original Parliament record
Explore activity by topic or department
Written questions by answering department
4 Jul 2026–16 Oct 2026. One record per UIN and tabled date; the named department is not a measure of answer quality.
View as listWhat this shows and doesn't show
Published records only — not a full account of an MP’s work. How we work →